260 related articles for article (PubMed ID: 17215446)
1. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
Labinskyy V; Bellomo M; Chandler MP; Young ME; Lionetti V; Qanud K; Bigazzi F; Sampietro T; Stanley WC; Recchia FA
J Pharmacol Exp Ther; 2007 Apr; 321(1):165-71. PubMed ID: 17215446
[TBL] [Abstract][Full Text] [Related]
2. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure.
Lionetti V; Linke A; Chandler MP; Young ME; Penn MS; Gupte S; d'Agostino C; Hintze TH; Stanley WC; Recchia FA
Cardiovasc Res; 2005 Jun; 66(3):454-61. PubMed ID: 15914110
[TBL] [Abstract][Full Text] [Related]
3. The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
Brigadeau F; Gelé P; Wibaux M; Marquié C; Martin-Nizard F; Torpier G; Fruchart JC; Staels B; Duriez P; Lacroix D
J Cardiovasc Pharmacol; 2007 Jun; 49(6):408-15. PubMed ID: 17577106
[TBL] [Abstract][Full Text] [Related]
4. Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats.
Jozefowicz E; Brisson H; Rozenberg S; Mebazaa A; Gelé P; Callebert J; Lebuffe G; Vallet B; Bordet R; Tavernier B
Crit Care Med; 2007 Mar; 35(3):856-63. PubMed ID: 17255874
[TBL] [Abstract][Full Text] [Related]
5. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
Ogata T; Miyauchi T; Sakai S; Takanashi M; Irukayama-Tomobe Y; Yamaguchi I
J Am Coll Cardiol; 2004 Apr; 43(8):1481-8. PubMed ID: 15093887
[TBL] [Abstract][Full Text] [Related]
6. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure.
Shiroshita-Takeshita A; Brundel BJ; Burstein B; Leung TK; Mitamura H; Ogawa S; Nattel S
Cardiovasc Res; 2007 Apr; 74(1):75-84. PubMed ID: 17270161
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.
Ichihara S; Obata K; Yamada Y; Nagata K; Noda A; Ichihara G; Yamada A; Kato T; Izawa H; Murohara T; Yokota M
J Mol Cell Cardiol; 2006 Aug; 41(2):318-29. PubMed ID: 16806263
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway.
Pellieux C; Aasum E; Larsen TS; Montessuit C; Papageorgiou I; Pedrazzini T; Lerch R
J Mol Cell Cardiol; 2006 Sep; 41(3):459-66. PubMed ID: 16859699
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
Aasum E; Khalid AM; Gudbrandsen OA; How OJ; Berge RK; Larsen TS
J Mol Cell Cardiol; 2008 Jan; 44(1):201-9. PubMed ID: 17931655
[TBL] [Abstract][Full Text] [Related]
10. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
11. Effects of an orally effective endothelin-A receptor antagonist in dogs with pacing-induced heart failure.
McConnell PI; Wang W; Zucker IH
Nebr Med J; 1996 Nov; 81(11):349-55. PubMed ID: 8979712
[TBL] [Abstract][Full Text] [Related]
12. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure.
Osorio JC; Stanley WC; Linke A; Castellari M; Diep QN; Panchal AR; Hintze TH; Lopaschuk GD; Recchia FA
Circulation; 2002 Jul; 106(5):606-12. PubMed ID: 12147544
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure.
Lei B; Lionetti V; Young ME; Chandler MP; d'Agostino C; Kang E; Altarejos M; Matsuo K; Hintze TH; Stanley WC; Recchia FA
J Mol Cell Cardiol; 2004 Apr; 36(4):567-76. PubMed ID: 15081316
[TBL] [Abstract][Full Text] [Related]
14. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model.
Zhang Y; Popovic ZB; Bibevski S; Fakhry I; Sica DA; Van Wagoner DR; Mazgalev TN
Circ Heart Fail; 2009 Nov; 2(6):692-9. PubMed ID: 19919995
[TBL] [Abstract][Full Text] [Related]
15. Glucose-6-phosphate dehydrogenase-derived NADPH fuels superoxide production in the failing heart.
Gupte SA; Levine RJ; Gupte RS; Young ME; Lionetti V; Labinskyy V; Floyd BC; Ojaimi C; Bellomo M; Wolin MS; Recchia FA
J Mol Cell Cardiol; 2006 Aug; 41(2):340-9. PubMed ID: 16828794
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin.
Metais C; Forcheron F; Abdallah P; Basset A; Del Carmine P; Bricca G; Beylot M
Metabolism; 2008 Jul; 57(7):946-53. PubMed ID: 18555836
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of a limited number of genes contributes to cardiac decompensation during chronic ventricular tachypacing in dogs.
Ojaimi C; Qanud K; Hintze TH; Recchia FA
Physiol Genomics; 2007 Mar; 29(1):76-83. PubMed ID: 17164392
[TBL] [Abstract][Full Text] [Related]
18. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
Nikolaidis LA; Elahi D; Hentosz T; Doverspike A; Huerbin R; Zourelias L; Stolarski C; Shen YT; Shannon RP
Circulation; 2004 Aug; 110(8):955-61. PubMed ID: 15313949
[TBL] [Abstract][Full Text] [Related]
19. Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes.
Guo Y; Jolly RA; Halstead BW; Baker TK; Stutz JP; Huffman M; Calley JN; West A; Gao H; Searfoss GH; Li S; Irizarry AR; Qian HR; Stevens JL; Ryan TP
Toxicol Sci; 2007 Apr; 96(2):294-309. PubMed ID: 17255113
[TBL] [Abstract][Full Text] [Related]
20. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats.
Zhao X; Li LY
Am J Nephrol; 2008; 28(4):598-606. PubMed ID: 18277067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
